Squarepoint Ops LLC Savara Inc Transaction History

Squarepoint Ops LLC

$80.7 Billion
Q1 2025

A detailed history of Squarepoint Ops LLC transactions in Savara Inc stock. As of the latest transaction made, Squarepoint Ops LLC holds 75,350 shares of SVRA stock, worth $160,495. This represents 0.0% of its overall portfolio holdings.

Number of Shares

75,350

Previous 122,635 38.56%

Holding current value

$160,495

Previous $376,000 44.68%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$2.32 - $3.14 $109,701 - $148,474	-47,285 Reduced 38.56%	75,350 $208,000
Q4 2024 Feb 14, 2025	BUY	$2.94 - $4.07 $230,907 - $319,657	78,540 Added 178.12%	122,635 $376,000
Q3 2024 Nov 14, 2024	SELL	$3.96 - $5.07 $269,846 - $345,485	-68,143 Reduced 60.71%	44,095 $186,000
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $410,791 - $599,350	112,238 New	112,238 $452,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.82 $25,929 - $45,700	16,206 New	16,206 $31,000
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.29 $65,665 - $99,585	-43,487 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.17 - $2.33 $50,879 - $101,324	43,487 New	43,487 $90,000
Q4 2020 Feb 16, 2021	SELL	$1.0 - $1.47 $19,555 - $28,745	-19,555 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$1.09 - $2.21 $58,004 - $117,605	-53,215 Reduced 73.13%	19,555 $21,000
Q2 2020 Aug 14, 2020	BUY	$1.8 - $3.05 $130,986 - $221,948	72,770 New	72,770 $181,000
Q1 2020 May 15, 2020	SELL	$1.91 - $4.08 $84,425 - $180,344	-44,202 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.71 - $4.91 $31,383 - $217,031	44,202 New	44,202 $198,000
Q2 2019 Aug 14, 2019	SELL	$2.37 - $11.7 $36,749 - $181,420	-15,506 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$6.71 - $8.6 $104,045 - $133,351	15,506 New	15,506 $114,000

Others Institutions Holding SVRA

# of Institutions

142

Shares Held

162M

Call Options Held

54.8K

Put Options Held

4.1K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $243M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account

Squarepoint Ops LLC Savara Inc Transaction History